



Press Release

Wednesday, April 21, 2010

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

STRIDES ARCOLAB ANNOUNCES USFDA APPROVAL FOR METOPROLOL TARTRATE INJECTION

APPROVAL MOMENTUM CONTINUES - TOTAL APPROVALS IN STERILE SPACE AT 22


Strides Arcolab Limited (Strides) today announced receipt of approval for its Abbreviated New Drug Application (ANDA) to Market Metoprolol Tartrate injection, USP (Metoprolol) commonly used in the treatment of acute myocardial infarction (AMI). Metoprolol will be sold in latex-free 5 mg per 5 mL vials . According to the American Heart Association, an estimated 1.4 million people annually will suffer a heart attack or AMI. IMS data indicates 2009 sales of Metoprolol approximated \$13 million. This is expected to be launched shortly.

Ravi Seth, Chief Executive Officer – International Operations of Strides stated: “We are delighted with the receipt of the third product approval from the USFDA within 10 days which reflects the strong development capabilities of Strides. This is an important addition to cardiovascular care portfolio of the partnership with Sagent, which already includes Adenosine vials and Labetalol vials , and has received 7 ANDA approvals till date.”

Metoprolol is the sixth product being launched under the partnership between Strides and Sagent Pharmaceuticals wherein Strides is developing and supplying more than 25 injectable products for the U.S. market which will be marketed by Sagent.

About Metoprolol Tartrate Injection

Metoprolol is the generic equivalent of Novartis Pharmaceutical Corporation’s Lopressor® (Metoprolol Tartrate Injection, USP). Metoprolol is a selective beta1-adrenoreceptor blocking agent that is indicated in the treatment of hemodynamically stable patients with definite or suspected AMI to reduce cardiovascular mortality. Treatment with intravenous Metoprolol can be initiated as soon as the patient’s clinical condition allows. Alternatively, treatment can begin within 3 to 10 days of the acute event.



Metoprolol is contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure. It is further contraindicated in patients with a heart rate < 45 beats/min; second- and third-degree heart block; significant first-degree heart block (P-R interval = 0.24 sec); systolic blood pressure < 100 mmHg; or moderate-to-severe cardiac failure.

About Strides Arcolab Limited:

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with marketing presence in more than 60 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore. Additional information is available at the company's website at www.stridesarco.com.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence™ and learn more about Sagent, please visit www.SagentPharma.com.

For further information, please contact:

Mr. Ravi Seth CEO – International Operations Ph: +91 80 6658 0121	Mr. Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 98803 76648 Email: maheshn@corvoshandwick.co.in
Mr. N Kannan, Company Secretary (Investors) Tel : +91 80 6658 0751	Ms. Kasturi Wasmatkar, Corporate Voice/ Weber Shandwick Mobile: 99167 28393 Email: kasturi@corvoshandwick.co.in
Ms. Melissa Arulappan (Media) Tel: +91 98450 22389	

